查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832121

自體免疫疾病治療市場（按藥物類別、作用機制、給藥途徑、適應症、分銷管道和最終用戶分類）—2025-2032 年全球預測

Autoimmune Disease Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，自體免疫疾病治療市場將成長至 2,121.9 億美元，複合年成長率為 7.74%。

主要市場統計數據
基準年2024年 1167.9億美元
預計2025年 1258.6億美元
預測年份：2032年 2121.9億美元
複合年成長率（%） 7.74%

高度重視臨床創新、商業性複雜性和政策驅​​動因素，這些因素正在共同重新定義自體免疫疾病的治療策略

本執行摘要概述了重塑自體免疫疾病治療格局的臨床、商業和政策格局。它綜合了治療方法的最新進展、作用機制的演變、給藥途徑的轉變以及分銷和醫療服務模式的變化。它強調了科學創新如何與報銷壓力、供應鏈脆弱性以及日益成長的以患者為中心的醫療期望相互交織，從而創造了一個需要敏捷戰略響應的複雜環境。

引言從治療差異化和運作複雜性的角度組裝了競爭格局。生物製藥正在重新定義多種適應症的治療標準，生物相似藥則為支付者和醫療保健提供者拓展了選擇。同時，口服小分子藥物和標靶抑制劑正在改變患者的偏好和依從性模式。這些動態在監管審查日益嚴格、注重真實世界證據以及支付方將療效與報銷掛鉤的背景下呈現。結果是，市場不僅獎勵療效和給藥方式方面的創新，也獎勵在商業化、可及性策略和相關人員參與方面卓越的創新。

本節旨在幫助讀者評估後續分析，包括技術變革、政策影響、細分洞察和區域差異。本章節優先採用綜合觀點，平衡臨床前景與製造、分銷和市場准入等實際考量。

科學突破、付款人壓力和以患者為中心的交付模式如何融合，重新定義自體免疫療法的競爭和臨床動態

在科學進步、監管格局演變以及患者和付款人期望不斷變化等因素的推動下，自體免疫療法領域正在經歷一系列變革性轉變。治療方法創新不再局限於漸進式改進，如今涵蓋了新型生物製劑、選擇性日益增強的細胞激素抑制劑，以及挑戰傳統腸外給藥優勢的口服標靶治療。這些進展正在加速針對B細胞耗竭和多種白細胞介素路徑等機制的開發計畫。同時，JAK抑制劑選擇性的提高促使人們重新評估獲益-風險權衡及其在治療流程中的地位。

同時，多個監管轄區內生物相似藥框架的日趨成熟，正在改變競爭動態，並加速支付方和醫療保健系統之間的成本控制策略。因此，原廠藥製造商正在追求差異化的價值提案，例如創新劑型、緩釋技術以及包含病患支援和依從性工具的配套服務。轉向以病人為中心的醫療模式的轉變也提升了給藥途徑的重要性。雖然口服療法因其便利性和依從性潛力而日益普及，但支持皮下自主給藥和居家照護的輸液服務正在重新定義慢性病治療的提供方式。

遠端監控、數位化依從性平台和整合資料流等技術推動因素正在擴增實境世界證據的生成，並支援基於結果的合約。這些轉變正在重塑競爭格局，為新治療方法創造新的切入點，並要求研發、監管事務、商業策略和供應鏈營運之間進行跨職能協調。

評估2025年關稅變化對供應鏈彈性、製造業在地化和商業准入策略的綜合影響

貿易和關稅制度的政策變化可能對全球醫藥供應鏈的經濟和物流產生重大影響，預計到2025年，累積影響將迫使產業相關人員重新評估其採購、生產和定價策略。某些投入品和成品的關稅上調將加劇依賴跨境原料藥、生技藥品成分和專用包裝的製造商的成本壓力。對於需要複雜低溫運輸物流和多組件供應網路的治療藥物而言，這些壓力尤其嚴峻。

為了應對這項挑戰，製造商正在多元化採購，加快區域製造投資，並協商更靈活的供應商條款，以保護生產免受關稅波動的影響。支付方和醫療系統可能會透過加強處方集管理並優先考慮具有成本效益的替代方案來應對不斷上升的採購成本。同時，製造商擴大考慮整體醫療成本，這不僅涵蓋購置價格，還涵蓋患者療效、依從性益處以及醫療保健利用率的降低，這有助於緩解關稅造成的利潤率壓縮。

在物流方面，關稅將延長前置作業時間，並導致庫存維修成本上升，因為企業需要建立緩衝庫存來應對關稅相關的中斷。監管和海關的複雜性可能會進一步減緩產品運輸，並使跨多個司法管轄區的臨床供應運作變得複雜。總體而言，2025年的累積關稅環境將鼓勵企業採取優先考慮供應鏈彈性、與製造外包和物流合作夥伴密切合作以及主動與付款人互動的策略，以在管理可負擔性問題的同時，保持藥品的可及性。

我們透過對藥物類別、作用機制、給藥途徑、適應症、分銷管道和最終用戶進行全面細分分析，明確策略和管理問題。

細分提供了一個實用的視角，可用於評估臨床差異化和商業機會的契合點。按藥物類別分類，市場包括生物製藥、生物相似藥和小分子化合物，其中生物製藥進一步細分為融合蛋白、單株抗體和胜肽。依作用機制，療法分為B細胞耗竭劑、白細胞介素抑制劑、JAK抑制劑和TNF抑制劑；白細胞介素抑制劑進一步分為IL17抑制劑、IL23抑制劑和IL6抑制劑；JAK抑制劑分為JAK1抑制劑、JAK1/2抑制劑和JAK3抑制劑。

給藥途徑細分追蹤口服和腸外藥物選擇。口服製劑包括膠囊、溶液和錠劑，腸外給藥包括靜脈注射和皮下給藥。給藥途徑的差異會影響病人的偏好、依從性、實務負擔和居家照護的可行性。基於適應症的細分涵蓋發炎性腸道疾病、狼瘡、多發性硬化症、牛皮癬和類風濕性關節炎。發炎性腸道疾病進一步細分為克隆氏症和潰瘍性大腸炎，牛皮癬細分為斑塊型乾癬和乾癬性關節炎。銷售管道細分區分線下和線上管道，這會影響患者的存取模式、專業藥房參與度和數位支援服務。最後，最終用戶細分涵蓋診所、居家醫療機構和醫院，這決定了行政物流、報銷代碼和提供者培訓需求。

綜合起來，解讀這些細分維度可以揭示哪些臨床創新有潛力帶來差異化的商業性回報，以及哪些領域需要將治療進展轉化為可及的醫療服務所需的營運投資。例如，針對IL23通路、用於皮下給藥的單株抗體與口服JAK1抑制劑的商業化需求不同，包括生產重點、病患支持生態系和經銷夥伴。

由於監管、付款人和製造環境不同，美洲、歐洲、中東和非洲以及亞太地區的市場進入和發布策略有何不同

區域動態對研發重點、監管途徑、付款人行為和准入策略的影響存在差異。在美洲，定價和報銷討論在很大程度上受到人們對付款人主導的處方集管理和基於價值的安排的興趣日益濃厚的影響，而商業性成功往往取決於強大的患者援助計劃和專業藥房整合。集中監管途徑和集中採購結構與不同的國家報銷標準共存，為策略定價和自適應上市排序創造了機會，盡可能利用區域監管協調。亞太市場的特點是法律規範快速發展、本地製造能力不斷增強以及付款人格局多樣化。打入市場策略通常強調成本效益高的製造、與本地契約製造的合作以及反映本地醫療保健提供模式的客製化准入計劃。

每個區域叢集都需要採用不同的臨床開發、監管參與和商業化方法。美洲地區可能優先考慮支持基於結果的合約並能證明對醫療保健利用產生實際影響的證據包，而歐洲、中東和非洲地區通常需要細緻入微的定價策略以及與多個國家機構的合作。亞太地區的策略通常在加快監管核准與可擴展的生產和分銷夥伴關係之間取得平衡，以應對不同的可及性和可負擔性限制。在產品規劃初期認知到這些區域差異有助於確定臨床實驗的場地選擇、製造地和上市順序，從而同時滿足臨床和商業目標。

專注於科學差異化、卓越製造和付款人一致證據生成的競爭格局將決定整個治療領域的公司策略

自體免疫療法的競爭態勢體現在大型生物製藥公司、專業生物技術公司、受託製造製造商以及新興生物相似藥參與企業的混合競爭中。主要企業正在投資下一代生技藥品、精準靶向小分子藥物以及將療法與數位化依從性和監測解決方案相結合的組合療法。策略夥伴關係、授權協議和定向授權是加速產品線多元化和獲取新機制的常用策略，無需承擔從頭發現的全部成本。

生產和供應鏈能力日益成為競爭優勢，尤其對於需要低溫運輸物流的複雜生技藥品和治療藥物。能夠展示在地化生產、穩健的品質系統和靈活供應鏈的公司，能夠更好地降低關稅和物流風險，並支援快速擴大規模。在商業方面，價值表達和付款人參與正在演變為複雜的、數據主導的對話。積極產生並分享真實世界證據和患者共用結果的公司更有可能獲得優先處方權，並參與基於結果的安排。

規模較小的公司和新興企業正在利用利基差異化優勢，例如高度選擇性的標靶途徑和新型遞送技術，創造收購和與大型企業合作的機會。同時，生物相似藥的參與企業正在加劇現有藥物類別的價格競爭，迫使原廠藥公司採取生命週期策略，強調透過改進配方、提供便利性和提供一體化服務來實現差異化。總體而言，競爭格局有利於那些將科學差異化、卓越製造和以付款人為中心的價值展示相結合的整合策略。

領導者可以採取切實可行的策略行動，以加強其供應鏈、證據產生和差異化價值提案，加速採用並確保永續的獲取

行業領導者應優先採取一系列切實行動，將科學進步轉化為永續的商業性價值。首先，投資於供應鏈韌性，包括實現採購多元化、擴大區域產能以及簽訂靈活的供應商協議，以降低關稅和物流衝擊的影響。其次，將現實世界結果和健康經濟終點納入臨床試驗，以符合付款方的證據需求，促進報銷談判，並創造基於價值的合約機會。

第三，我們將追求差異化的產品和服務組合，將治療效益與依從性支持、數位監控和病患教育相結合，以更廣泛地衡量價值。第四，我們將採用投資組合策略，在高利潤率的生技藥品與策略性選擇的生物相似藥和小分子藥物機會之間取得平衡，以保持在成本敏感型市場的准入。第五，我們將根據地區客製化市場進入和商業化策略，優先考慮監管途徑、本地製造夥伴關係關係以及能夠反映美洲、歐洲、中東和非洲以及亞太地區細微差別的分銷模式。

領導者還應儘早正式製定付款人參與計劃，利用迭代證據生成來完善價值提案，並協商創新的合約模式。最後，投資跨職能能力，包括監管、衛生經濟學、真實世界證據和數位健康整合，以確保科學進步轉化為持續的臨床應用，並實現跨醫療環境的永續可及永續。

專家研究、監管分析、臨床專家訪談以及產品線格局的透明綜合支持強力的策略建議

本執行摘要所依據的研究整合了多種證據流，旨在提供切實可行的策略洞察。我們對同行評審文獻、監管指南文件和公開的臨床試驗註冊庫進行了二次性證據審查，以繪製治療進展和安全性概況。與臨床醫生、衛生經濟學家、付款人和供應鏈專業人士進行的專家訪談定性檢驗了觀察到的趨勢，並確定了營運影響。產品線格局和作用機轉圖譜將研發軌跡與臨床未滿足需求和競爭定位進行了匹配。

我們的比較監管分析檢視了主要司法管轄區的核准途徑、生物相似藥框架和定價機制，以確定准入途徑和潛在障礙。透過回顧一些值得關注的上市和市場進入安排的案例研究，為付款人談判和患者援助計劃設計提供了最佳實踐建議。調查方法的局限性包括：缺乏專有商業資訊的獲取途徑、依賴現有的公共數據，以及臨床開發和政策本身的動態性（在本分析截止日期之後可能會發生變化）。在可能的情況下，我們的研究結果會透過多個資訊來源進行三角檢驗，並經過同行評審，以增強穩健性並減少偏差。

該研究遵循透明度和可重複性原則、記錄方法、納入標準和專家意見類型，分析強調定性綜合而不是定量預測，以確保對決策者俱有實際意義。

將治療方法創新、營運彈性和付款人參與度結合成一個有凝聚力的藍圖，以實現持續的可及性和商業性成功

自體免疫治療領域正處於曲折點，科學進步、支付方審查和不斷發展的治療模式交織在一起，既帶來了風險，也帶來了機會。生物製藥的治療創新正在拓展治療選擇，並實現更個人化的治療，但這些進步也帶來了營運和商業上的複雜性。將臨床差異化與彈性製造、積極主動的支付方參與以及以患者為中心的交付模式相結合的製造商將最有可能獲得長期價值。

法律規範，因此需要製定根據當地實際情況客製化試驗設計、供應佈局和上市策略的策略。資費變化和供應鏈中斷的累積影響凸顯了製定策略規劃的必要性，該規劃需要在成本管理與患者獲得不間斷的藥物取得之間取得平衡。最終，在這一領域的成功將取決於組織能否將科學創新轉化為以真實世界證據為支撐的令人信服的價值故事，同時保持營運靈活性以適應政策和市場變化。

研發、商業、監管和供應鏈職能部門的相關人員必須密切合作，將見解轉化為可操作的藍圖，以維持存取權、向付款人展示價值並改善病患的治療效果。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對雙重自體免疫途徑的雙特異性抗體的廣泛應用有望提高療效
  • 將數位健康平台的真實世界證據整合到自體免疫疾病藥物開發決策中
  • 腫瘤衍生的JAK抑制劑迅速用於治療發炎和自體免疫疾病
  • 精準醫療舉措推動多發性硬化症個人化胜肽疫苗研發進展
  • 生技新興企業與大型製藥公司在新型 S1P 受體調變器研發管線的合作日益加強
  • 增加對皮下製劑的監管核准，以提高患者對類風濕性關節炎治療的依從性
  • 擴大遠端醫療主導的疾病監測和對慢性自體免疫疾病治療通訊協定的依從性支持
  • FcRn 抑制劑作為減少天皰瘡致病性 IgG 自體抗體的第一線治療藥物的出現

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章自體免疫疾病藥物市場（依藥物類別）

  • 生物製藥
    • 融合蛋白
    • 單株抗體
    • 胜肽
  • 生物相似藥
  • 小分子

第9章自體免疫疾病藥物市場（依作用機制）

  • B細胞耗竭者
  • 白血球介素抑制劑
    • IL17抑制劑
    • IL23抑制劑
    • IL6抑制劑
  • Jak抑制劑
    • Jak1抑制劑
    • Jak1/2抑制劑
    • Jak3抑制劑
  • TNF抑制劑

第10章自體免疫疾病藥物市場（依給藥途徑）

  • 口服
    • 膠囊
    • 解決方案
    • 藥片
  • 腸外
    • 靜脈
    • 皮下

第11章自體免疫疾病藥物市場（按適應症）

  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 狼瘡
  • 多發性硬化症
  • 銀屑病
    • 斑塊型乾癬
    • 乾癬性關節炎
  • 類風濕性關節炎

第12章自體免疫疾病治療市場（按通路）

  • 離線
  • 線上

第 13 章自體免疫疾病治療市場（按最終用戶）

  • 診所
  • 居家照護環境
  • 醫院

第14章自體免疫疾病治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章自體免疫疾病治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國自體免疫疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Roche Holding AG
    • Novartis AG
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • Eli Lilly and Company
    • Amgen Inc.
    • Merck & Co., Inc.
Product Code: MRR-436901065FE5

The Autoimmune Disease Drugs Market is projected to grow by USD 212.19 billion at a CAGR of 7.74% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 116.79 billion
Estimated Year [2025] USD 125.86 billion
Forecast Year [2032] USD 212.19 billion
CAGR (%) 7.74%

High-level orientation to clinical innovation, commercial complexity, and policy drivers that are jointly redefining autoimmune disease treatment strategies

This executive summary synthesizes current clinical, commercial, and policy developments that are reshaping the autoimmune therapeutics landscape. It synthesizes recent advances in therapeutic modalities, evolving mechanisms of action, shifts in routes of administration, and changing distribution and care-delivery models. The narrative highlights where scientific innovation intersects with reimbursement pressures, supply chain fragility, and heightened expectations for patient-centered care, producing a complex environment that demands agile strategic responses.

The introduction frames the competitive arena in terms of therapeutic differentiation and operational complexity. Biologic therapies have redefined standards of care across multiple indications, while biosimilars are increasing options for payers and providers. Simultaneously, oral small molecules and targeted inhibitors are altering patient preferences and adherence patterns. These dynamics unfold against a backdrop of intensified regulatory scrutiny, greater emphasis on real-world evidence, and payer initiatives designed to link outcomes to payment. The result is a market that rewards innovation in therapeutic efficacy and delivery, as well as excellence in commercialization, access strategy, and stakeholder engagement.

This section prepares the reader to evaluate subsequent analyses on technological shifts, policy impacts, segmentation insights, and regional differences. It prioritizes an integrated view that balances clinical promise with pragmatic considerations for manufacturing, distribution, and market access.

How scientific breakthroughs, payer pressures, and patient-centered delivery models are converging to redefine competitive and clinical dynamics in autoimmune therapeutics

The autoimmune therapeutics landscape is experiencing a series of transformative shifts driven by scientific advances, regulatory evolution, and changing patient and payer expectations. Therapeutic innovation is no longer limited to incremental improvements; it now includes novel biologic constructs, increasingly selective cytokine inhibitors, and oral targeted therapies that challenge traditional parenteral dominance. These advances have accelerated targeted development programs against mechanisms such as B cell depletion and multiple interleukin pathways, while the refinement of JAK inhibitor selectivity is prompting a reappraisal of benefit-risk trade-offs and positioning in treatment algorithms.

Concurrently, the maturation of biosimilar frameworks in several regulatory jurisdictions is altering competitive dynamics and accelerating cost-containment strategies among payers and health systems. This has prompted originator manufacturers to pursue differentiated value propositions, including novel formulations, extended-release technologies, and bundled service offerings that incorporate patient support and adherence tools. The shift toward patient-centric care models has also elevated the importance of route of administration; oral therapies are gaining traction for convenience and adherence potential, while subcutaneous self-administration and homecare-enabled intravenous services redefine where chronic treatment occurs.

Technological enablers such as remote monitoring, digital adherence platforms, and integrated data streams are enhancing real-world evidence generation and supporting outcomes-based contracting. Taken together, these shifts are remapping the competitive field, creating new entry points for novel modalities, and demanding cross-functional coordination between R&D, regulatory affairs, commercial strategy, and supply chain operations.

Assessing the compound effects of evolving tariff regimes on supply chain resilience, manufacturing localization, and commercial access strategies through 2025

Policy changes in trade and tariff regimes can materially affect the economics and logistics of global pharmaceutical supply chains, and the cumulative effects projected through 2025 have prompted industry participants to reassess sourcing, manufacturing, and pricing strategies. Increased tariff exposure on certain inputs and finished goods amplifies cost pressures for manufacturers that rely on cross-border flows for active pharmaceutical ingredients, biologics components, and specialized packaging. These pressures are particularly acute for therapies that require complex cold-chain logistics and multi-component supply networks.

In response, manufacturers are diversifying sourcing footprints, accelerating regional manufacturing investments, and negotiating more flexible supplier terms to insulate production from tariff volatility. Payers and health systems may respond to higher procurement costs by intensifying formulary management and prioritizing cost-effective alternatives, which could accelerate uptake of lower-cost biosimilars and incentivize negotiations around value-based agreements. At the same time, manufacturers are increasingly examining total cost of care narratives that encompass not just acquisition price but also patient outcomes, adherence benefits, and reductions in healthcare utilization, which can mitigate tariff-driven margin compression.

Logistically, tariffs contribute to longer lead times and higher inventory carrying costs as companies build buffer stocks to manage tariff-related interruptions. Regulatory and customs complexity can further slow product movement and complicate multi-jurisdictional clinical supply operations. Overall, the cumulative tariff environment through 2025 encourages strategies that prioritize supply chain resilience, closer collaboration with contract manufacturers and logistics partners, and proactive engagement with payers to preserve access while managing affordability concerns.

Integrated segmentation analysis revealing how drug class, mechanism, route, indication, distribution, and end-user distinctions drive strategic and operational imperatives

Segmentation provides a practical lens to evaluate where clinical differentiation and commercial opportunity align. Based on drug class, the market comprises biologics, biosimilars, and small molecules, with biologics further divided into fusion proteins, monoclonal antibodies, and peptides; these distinctions matter for manufacturing complexity, regulatory pathways, and lifecycle management strategies. Based on mechanism of action, treatments are clustered across B cell depleting agents, interleukin inhibitors, JAK inhibitors, and TNF inhibitors, with interleukin inhibitors further parsed into IL17, IL23, and IL6 inhibitors and JAK inhibitors categorized into JAK1, JAK1/2, and JAK3 inhibitors; this mechanistic granularity informs target selection, safety monitoring, and competitive positioning within specific indications.

Route of administration segmentation tracks oral and parenteral options, where oral forms include capsules, solutions, and tablets and parenteral forms encompass intravenous and subcutaneous delivery; route differences affect patient preference, adherence, clinic burden, and homecare feasibility. Indication-based segmentation addresses inflammatory bowel disease, lupus, multiple sclerosis, psoriasis, and rheumatoid arthritis, noting that inflammatory bowel disease is further detailed into Crohn's disease and ulcerative colitis, while psoriasis includes plaque psoriasis and psoriatic arthritis; indication-level nuances dictate trial design, endpoints, and payer evidence requirements. Distribution channel segmentation distinguishes offline and online pathways, which impacts patient access models, specialty pharmacy engagement, and digital support services. Finally, end user segmentation covers clinics, homecare settings, and hospitals, and these care settings determine administration logistics, reimbursement codes, and provider training needs.

Interpreting these segmentation dimensions in combination highlights where clinical innovation can yield differentiated commercial returns and where operational investments will be necessary to translate therapeutic advances into accessible care. For example, a monoclonal antibody targeting an IL23 pathway intended for subcutaneous administration will have different commercialization imperatives than an oral JAK1 inhibitor, including distinct manufacturing priorities, patient support ecosystems, and distribution partnerships.

How divergent regulatory, payer, and manufacturing landscapes across the Americas, Europe Middle East & Africa, and Asia-Pacific demand tailored market access and launch strategies

Regional dynamics shape R&D priorities, regulatory pathways, payer behavior, and access strategies in distinct ways. In the Americas, pricing and reimbursement debates are heavily influenced by payer-driven formulary management and an increasing focus on value-based arrangements, while commercial success often hinges on robust patient support programs and specialty pharmacy integration. European, Middle Eastern, and African markets present a mosaic of regulatory frameworks and pricing pressures; centralized regulatory pathways and joint procurement mechanisms coexist with diverse national reimbursement criteria, creating opportunities for strategic pricing and adaptive launch sequencing that leverage regional regulatory harmonization where possible. Asia-Pacific markets are notable for rapidly evolving regulatory frameworks, growing local manufacturing capacity, and heterogeneous payer landscapes; market entry strategies commonly emphasize cost-efficient manufacturing, partnerships with regional contract manufacturers, and tailored access programs that reflect local healthcare delivery models.

Each regional cluster demands differentiated approaches to clinical development, regulatory engagement, and commercialization. The Americas may prioritize evidence packages that support outcomes-based contracting and demonstrate real-world impact on healthcare utilization, whereas the Europe, Middle East & Africa region often requires nuanced pricing strategies and engagement with multiple national agencies. Asia-Pacific strategies frequently balance accelerated regulatory approvals with scalable manufacturing and distribution partnerships to meet diverse access and affordability constraints. Recognizing these regional distinctions early in product planning enables optimized trial site selection, manufacturing footprint decisions, and launch sequencing that align with both clinical and commercial objectives.

Competitive imperatives emphasizing scientific differentiation, manufacturing excellence, and payer-aligned evidence generation that shape corporate strategies across the therapeutic landscape

Competitive dynamics across the autoimmune therapeutics space are characterized by a mix of large biopharma incumbents, specialized biotech innovators, contract manufacturing organizations, and emerging biosimilar entrants. Leading companies are investing in next-generation biologics, precision-targeted small molecules, and combination approaches that pair therapeutic agents with digital adherence or monitoring solutions. Strategic collaborations, licensing agreements, and targeted in-licensing remain common tactics to accelerate pipeline diversification and to access novel mechanisms without incurring the full costs of de novo discovery.

Manufacturing and supply chain capabilities are increasingly central competitive differentiators, particularly for complex biologics and therapies requiring cold-chain logistics. Firms that can demonstrate localized manufacturing, robust quality systems, and flexible supply architectures are better positioned to mitigate tariff and logistics risks and to support rapid scale-up. On the commercial front, value articulation and payer engagement are evolving into sophisticated, data-driven dialogues; companies that proactively generate and share real-world evidence and patient-reported outcomes are more likely to secure preferred formulary positions and to participate in outcomes-based arrangements.

Smaller companies and startups are leveraging niche differentiation, such as highly selective pathway targeting or novel delivery technologies, to create acquisition or partnership opportunities with larger players. Meanwhile, biosimilar entrants are intensifying price competition in established classes, prompting originator companies to pursue lifecycle strategies that emphasize differentiation through improved formulations, convenience, and integrated services. Overall, the competitive environment rewards integrated strategies that combine scientific differentiation, manufacturing excellence, and payer-centered value demonstration.

Actionable strategic moves for leaders to strengthen supply chains, evidence generation, and differentiated value propositions that accelerate adoption and ensure sustainable access

Industry leaders should prioritize a set of practical actions to convert scientific advances into sustainable commercial value. First, invest in supply chain resilience by diversifying sourcing, expanding regional manufacturing capabilities, and developing flexible supplier agreements that reduce exposure to tariff and logistics shocks. Second, align clinical development with payer evidence needs by embedding real-world outcomes and health-economic endpoints into trials, thereby facilitating reimbursement discussions and enabling value-based contracting opportunities.

Third, pursue differentiated product and service bundles that combine therapeutic efficacy with adherence support, digital monitoring, and patient education to capture a broader measure of value. Fourth, adopt a portfolio approach that balances high-margin biologics with strategically chosen biosimilar or small-molecule opportunities to preserve access in cost-sensitive markets. Fifth, tailor market entry and commercialization strategies by region, prioritizing regulatory pathways, local manufacturing partnerships, and distribution models that reflect the Americas, Europe, Middle East & Africa, and Asia-Pacific nuances.

Leaders should also formalize payer engagement plans early, using iterative evidence generation to refine value propositions and to negotiate innovative contracting models. Finally, invest in cross-functional capabilities-regulatory affairs, health economics, real-world evidence, and digital health integration-to ensure that scientific progress translates into durable clinical uptake and sustainable access across diverse care settings.

Transparent synthesis of peer-reviewed research, regulatory analysis, clinical expert interviews, and pipeline landscaping to support robust strategic recommendations

The research underpinning this executive summary synthesizes multiple evidence streams to deliver actionable strategic insight. Secondary evidence reviews were conducted across peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic advances and safety profiles. Targeted expert interviews with clinicians, health economists, payers, and supply chain specialists provided qualitative validation of observed trends and clarified operational implications. Pipeline landscaping and mechanism-of-action mapping were used to align R&D trajectories with clinical unmet needs and competitive positioning.

Comparative regulatory analysis examined approval pathways, biosimilar frameworks, and pricing mechanisms across major jurisdictions to identify access levers and potential barriers. Case study review of notable launches and market-access arrangements informed best-practice recommendations on payer negotiation and patient support program design. Limitations of the methodology include reliance on available public data where proprietary commercial intelligence was not accessible, and the inherently dynamic nature of clinical development and policy which may evolve after the cut-off for this analysis. Wherever possible, findings were triangulated across multiple sources and reviewed by subject-matter experts to enhance robustness and reduce bias.

The research adheres to principles of transparency and reproducibility: methods, inclusion criteria, and the types of expert inputs are documented, and the analysis emphasizes qualitative synthesis over quantitative projection to ensure practical relevance for decision-makers.

Concluding synthesis that links therapeutic innovation, operational resilience, and payer engagement into a cohesive blueprint for achieving durable access and commercial success

The autoimmune therapeutics landscape is at an inflection point where scientific progress, payer scrutiny, and evolving care models intersect to create both risk and opportunity. Therapeutic innovation across biologics, biosimilars, and targeted small molecules is expanding treatment options and enabling more personalized care, but these advances come with heightened operational and commercial complexity. Manufacturers that integrate clinical differentiation with resilient manufacturing, proactive payer engagement, and patient-centered delivery models will be best positioned to capture long-term value.

Regional variability in regulatory frameworks, payer priorities, and manufacturing capacity requires tailored strategies that align trial design, supply footprints, and market access tactics with local realities. The cumulative impact of tariff changes and supply chain disruptions underscores the need for strategic planning that balances cost management with uninterrupted patient access. Ultimately, success in this arena will depend on an organization's ability to translate scientific innovation into compelling value narratives supported by real-world evidence, while maintaining operational agility to adapt to policy and market shifts.

Stakeholders across R&D, commercial, regulatory, and supply chain functions must collaborate closely to convert insights into executable roadmaps that preserve access, demonstrate value to payers, and improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of bispecific antibodies targeting dual autoimmune pathways for enhanced efficacy
  • 5.2. Integration of real-world evidence from digital health platforms in autoimmune drug development decisions
  • 5.3. Surge in oncology-derived JAK inhibitors being repurposed for inflammatory autoimmune disorders
  • 5.4. Advancement of personalized peptide-based vaccines for multiple sclerosis under precision medicine initiatives
  • 5.5. Increased partnerships between biotech startups and big pharma for novel S1P receptor modulator pipelines
  • 5.6. Rising regulatory approvals of subcutaneous formulations improving patient adherence in rheumatoid arthritis therapies
  • 5.7. Expansion of telemedicine-driven disease monitoring and adherence support for chronic autoimmune treatment protocols
  • 5.8. Emergence of FcRn inhibitors as first-line therapy to reduce pathogenic IgG autoantibodies in pemphigus

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Fusion Proteins
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Peptides
  • 8.2. Biosimilars
  • 8.3. Small Molecules

9. Autoimmune Disease Drugs Market, by Mechanism Of Action

  • 9.1. B Cell Depleting Agents
  • 9.2. Il Inhibitors
    • 9.2.1. Il17 Inhibitors
    • 9.2.2. Il23 Inhibitors
    • 9.2.3. Il6 Inhibitors
  • 9.3. Jak Inhibitors
    • 9.3.1. Jak1 Inhibitors
    • 9.3.2. Jak1/2 Inhibitors
    • 9.3.3. Jak3 Inhibitors
  • 9.4. Tnf Inhibitors

10. Autoimmune Disease Drugs Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Capsule
    • 10.1.2. Solution
    • 10.1.3. Tablet
  • 10.2. Parenteral
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous

11. Autoimmune Disease Drugs Market, by Indication

  • 11.1. Inflammatory Bowel Disease
    • 11.1.1. Crohn's Disease
    • 11.1.2. Ulcerative Colitis
  • 11.2. Lupus
  • 11.3. Multiple Sclerosis
  • 11.4. Psoriasis
    • 11.4.1. Plaque Psoriasis
    • 11.4.2. Psoriatic Arthritis
  • 11.5. Rheumatoid Arthritis

12. Autoimmune Disease Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Autoimmune Disease Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Homecare Settings
  • 13.3. Hospitals

14. Autoimmune Disease Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Autoimmune Disease Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Autoimmune Disease Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Johnson & Johnson
    • 17.3.3. Roche Holding AG
    • 17.3.4. Novartis AG
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Bristol-Myers Squibb Company
    • 17.3.7. Sanofi S.A.
    • 17.3.8. Eli Lilly and Company
    • 17.3.9. Amgen Inc.
    • 17.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (